Connect with us

Business

Warning of Financial Cliff Thrusts Stock Market Lower

Published

on

The traders returned to work after the Thanksgiving holiday weekend to the same old fears about financial cliff in addition to the European debt crisis, and things didn’t seem to get any better during the first three days of the week.

In mid-day trading on Monday, the stock market declined as Washington policymakers and business groups argued over the correct rates for spending on taxing. In Europe, the leaders made attempts to cobble together one more loan bailout for Greece.

By afternoon, the industrial average of Dow Jones dropped to 12,919, by 91 points. The S&P’s 500 fell to 1,401 by 8 points, while the NASDAQ composite index went down to 2,960 by 7 points.

On the whole, it was a silent morning without any vital economic statement due in the United States and no major firms slated to make huge announcements.

What followed next was just a slight improvement in Asian stocks on Tuesday.

Portland-based Leader Capital’s co-portfolio manager, Scott Carmack told the fall was everything, but unavoidable looking at how the market surged previous week. It was one amongst the best weeks for Dow throughout the year and followed around 4 weeks of drops. Positive economic reports from China and Germany (in addition to Friday’s initial reports that holiday shopping had started strongly) assisted to thrust the market higher.

That turned out Monday to be a good day for cashing out on the gains of previous weeks, according to Carmack, particularly because the traders are not confident of how the financial cliff will influence the market for the remaining days of the year.

It is still hard to measure how this holiday shopping season will turn out to be for retailers, who depend highly on the Christmas season. The National Retail Federation (NRF) stated that 247 million shoppers visited the shopping websites and stores during the Thanksgiving weekend, which is up 9% when compared to a year back. On an average, they spent $423, up 6%.

Few are worried that the momentum will not last. Retailers like Target, Saks, and Macy’s were weak in early trading. Saks dropped 41 cents to $10.11, while Macy’s declined $1.55 to $40.17. The exception here was Abercrombie & Fitch, increasing 37 cents to $44.77.

Put the blame on the disturbing hangover of the financial cliff. That’s the time when higher taxes as well as cuts to government schemes, like Social Security and unemployment benefits, will step in at the yearend unless the White House and Congress work out a solution prior to that.

Continue Reading

Business

Top 3 Gainers: Zynga (NASDAQ:ZNGA), Eros International (NYSE:EROS), Borqs Technologies’ (BRQS)

Published

on

By

Zynga (NASDAQ:ZNGA) is up 2.5% after Benchmark reiterated its Buy rating in a look-ahead at Q2 earnings. The firm’s expecting a beat and solid guidance for Q3, and it’s raising its guidance for the fiscal year.

Tailwinds from the pandemic won’t dissipate easily, Benchmark suggests, and the videogame maker’s acquisition of Peak (and with it new “forever franchises” in Toon Blast and Toy Blast) will drive audience, bookings, margins and free cash flow, it says. The firm has an $11 price target, now implying 14% upside.

Eros International (NYSE:EROS) is up 5.8% today, making up the last week’s lost ground, after news that its streaming service Eros Now is partnering with Sony India (SNE +2.3%).

That will mean Eros Now’s app is pre-installed on selected Sony smart televisions in India, along with availability on a large base of existing models (Bravia E series and newer).

The country over the past year has seen a 25% growth in demand for smart TVs, fueled by overall industry growth of 15%, to a record 15M units/year.

Borqs Technologies’ (BRQS) personal safety tracker sees strong market with increased orders from the electronics retail chain in the US.

The boost in product demand comes ahead coronavirus pandemic that provides company to expect delivery of 250K units this year. It reflects over 3x the volume delivered in 2019, the year of its launch.

Borqs’ mobile personal safety devices designed particularly for senior citizens come with panic button, location tracking, and fall detection.

Continue Reading

Biotech

Biotech movers: Pfizer Inc. (PFE), Celgene Corporation (CELG)

Published

on

Pfizer Inc. (PFE) said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.

Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney’s office for the Southern District of New York.

Why ASDN Could Massively Outperform PFE in 2019

Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.

Bristol-Myers Squibb has been meeting with shareholders in Boston and New York over the last two weeks to try to salvage its $74 billion purchase of cancer drugmaker Celgene Corporation (CELG), the biggest acquisition announced so far this year.

Why Investors Are Calling ASDN the CELG of the Sky!

The deal, announced in January, was hard sell to Bristol shareholders from the start. The acquisition adds about $32 billion in fresh debt to Bristol’s balance sheet while assuming $20 billion in Celgene’s debt, the companies said at the time. After factoring in debt, the acquisition was the largest health-care deal on record, according to data compiled by Refinitiv.

Now, hedge funds Wellington Management and Starboard Value say the deal doesn’t sit well with them. Bristol has sent executives to New York to meet with institutional investors several times over the last two weeks and met with investors in Boston on Wednesday and Thursday, according to a person who briefed on the meetings.

Bristol-Myers declined to comment.

Continue Reading

Biotech

Big Losers: Corbus Pharmaceuticals Holdings, Inc. (CRBP), Petróleo Brasileiro S.A. – Petrobras (PBR)

Published

on

Corbus Pharmaceuticals Holdings, Inc. (CRBP)’s shares slumped as much as 16% to $6.94 on huge volume. The stock has been showing intense sell off suddenly after a bearish article on seekingalph.com by Alpha Exposure.

The article stated that Corbus has ties to investors convicted of or alleged to have committed securities fraud. We believe lenabasum has failed its major trials in SSc and CF. Lenabasum was also denied Breakthrough Therapy Designation in SSc. We believe lenabasum will fail in its pivotal SSc and Phase 2b CF trials. We are short Corbus with a price target of $0.50.

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

Petróleo Brasileiro S.A. – Petrobras (PBR) is expanding its ambitious divestment program and has “bold” plans for sales, the Brazilian state-run oil company’s chief executive said after the firm posted its first annual profit in five years.

On a conference call with analysts to discuss fourth-quarter results, CEO Roberto Castello Branco said selling non-core assets will be key to deleveraging.

Petrobras, as the company is known, can reduce its ratio of net debt to earnings before interest, taxes, depreciation and amortization, or EBITDA, to 1.5 or even to 1, he added.

The University of Chicago-educated CEO, who took the reins in early January, has long been vocal about the need to slim down the sprawling firm and focus on core activities such as exploration and production. Thursday’s comments were some of his most assertive on the matter.

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading
Advertisement

Trending